Stay updated on ACTT: Remdesivir for Severe COVID-19 Clinical Trial

Sign up to get notified when there's something new on the ACTT: Remdesivir for Severe COVID-19 Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the ACTT: Remdesivir for Severe COVID-19 Clinical Trial page

  1. Check
    today
    No Change Detected
  2. Check
    yesterday
    No Change Detected
  3. Check
    2 days ago
    Change Detected
    Summary
    The value of Revision has been updated from v2.8.0 to v2.8.1, indicating a recent revision in the content of the webpage.
    Difference
    0.1%
    Check dated 2024-06-13T22:01:10.000Z thumbnail image
  4. Check
    3 days ago
    No Change Detected
  5. Check
    5 days ago
    No Change Detected
  6. Check
    10 days ago
    Change Detected
    Summary
    The value on the webpage has changed from 7 to 8, indicating a modification in the number of investigational therapeutic agents being compared to a control arm in a multicenter trial evaluating the safety and efficacy of novel treatments for hospitalized adults diagnosed with COVID-19.
    Difference
    0.1%
    Check dated 2024-06-06T14:33:12.000Z thumbnail image
  7. Check
    25 days ago
    Change Detected
    Summary
    The webpage has been updated to include detailed eligibility criteria for participation in the study, specifying that participants must be hospitalized with symptoms suggestive of COVID-19 and provide informed consent. Previously, no information was provided about the participation criteria for collaborators and investigators.
    Difference
    12%
    Check dated 2024-05-22T21:03:52.000Z thumbnail image
  8. Check
    46 days ago
    Change Detected
    Difference
    0.6%
    Check dated 2024-04-30T22:51:16.000Z thumbnail image

Stay in the know with updates to ACTT: Remdesivir for Severe COVID-19 Clinical Trial

Enter your email address, and we'll notify you when there's something new on the ACTT: Remdesivir for Severe COVID-19 Clinical Trial page.